Understand the source comparison
Comparison Table: BPC-157 vs TB-500 vs Thymosin Beta-4 for Bursitis
Each peptide targets different aspects of the inflammatory and repair cascade. Here's how they compare in practical application. BPC-157 VEGF pathway activation, angiogenesis promotion in hypoxic tissue 250–500 mcg/day Once or twice daily Acute bursitis with s
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Each peptide targets different aspects of the inflammatory and repair cascade. Here's how they compare in practical application.
- BPC-157
- VEGF pathway activation, angiogenesis promotion in hypoxic tissue
- 250–500 mcg/day
- Once or twice daily
- Acute bursitis with suspected ischemia or poor healing response
- Strongest preclinical evidence for localised tissue repair; short half-life requires consistent dosing
- TB-500
- Actin binding, cell migration, cytokine downregulation (TNF-α, IL-6)
- 2–10 mg/week
- Twice weekly (loading) to weekly (maintenance)
- Subacute to chronic bursitis with persistent inflammation
- Longer half-life allows less frequent dosing; well-tolerated in most research models
- Thymosin Beta-4 (full-length)
- MMP modulation, fibrosis prevention, broader tissue remodelling
- 5–10 mg/week
- Twice weekly
- Chronic bursitis with fibrosis or calcification on imaging
- Most comprehensive anti-fibrotic effects; higher cost than TB-500 fragment